Search
Close this search box.
    • Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers
Search
Close this search box.
Syngene reports second quarter results for FY25

Revenue from operations increases sequentially by 13%

Read Press Release
Syngene recognized as one of India’s most sustainable companies by Business World magazine

91st position overall and the only CRDMO featured in the pharmaceutical sector

Syngene wins Asia Pacific Biologics CMO Excellence Awards 2024

Adjudged Best Biologics CMO in South Asia by IMAPAC

Manufacturing the drug substance for Zoetis’ first-in-class mAb osteoarthritis drug
Read Case Study
Syngene achieves silver in EcoVadis ESG assessment

Syngene has been awarded a Silver EcoVadis Medal for FY 2024, placing us among the top 15% of companies assessed.

Read Press Release
Previous slide
Next slide
Syngene reports second quarter results for FY25

Revenue from operations increases sequentially by 13%

Read Press Release
Syngene recognized as one of India’s most sustainable companies by Business World magazine

91st position overall and the only CRDMO featured in the pharmaceutical sector

Syngene wins Asia Pacific Biologics CMO Excellence Awards 2024

Adjudged Best Biologics CMO in South Asia by IMAPAC

Manufacturing the drug substance for Zoetis’ first-in-class mAb osteoarthritis drug
Read Case Study
Syngene achieves silver in EcoVadis ESG assessment

Syngene has been awarded a Silver EcoVadis Medal for FY 2024, placing us among the top 15% of companies assessed.

Read Press Release
Previous slide
Next slide

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

More
More

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

More
More

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

More
More

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

More
More

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

More
More

InstaVisit – Visit Syngene virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

View Now
View Now
Visit Syngene virtually with a 360 degree view of Syngene’s world-class facilities and capabilities
0 +

Active Clients

0

Collaborations with top 20 Pharma/Biotech companies

5200

Scientists

0

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents 

Latest News

View all
View all

Developing a Complex, First-of-its-kind Antiparasitic Drug for Dogs

More
News
12th Nov, 2024

Can India Leverage US Biosecure Act to Strengthen CRDMOs?

More
News
31st Oct, 2024

biologics Roundtable: the current landscape and future developments

More
News
29th Oct, 2024

Insights

View all
View all

Quantifying a biomarker in mice brain for treating mood and anxiety disorders

A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
More

Risk assessment strategy for nitrosamine drug substance-related impurities

The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.
More

Innovation at Syngene: Translatable models for improving cancer research

Syngene has developed orthotopic models validated against the standard of care and tumor models with 3D culture, which can help improve translatability and clinical relevance in cancer research.
More

Upcoming events

View all
View all

Spanish Drug Discovery Network

13th to 15th Nov
Valencia

ACT 2024 Annual Meeting

17th to 20th Nov
Austin, Texas

Organic24

18th to 20th Nov
Adelaide, AUS

Bio Manufacturing World Summit 2024 (BMWS 24)

19th to 21st Nov
San Diego

CPHI India

26th to 28th Nov
New Delhi

Biofit 2024

3rd & 4th Dec
Lille, France

Corporate Social Responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.
More
More

Governance

Behind consistent growth is good governance

More
More

Careers

Discover a world of opportunities

More
More

Annual Reports

Touching a billon lives through innnovation

More
More

Sign-up for our newsletter

© 2024. Syngene International Limited

Linkedin-in Youtube Facebook-f

Quick links

Business

Get in touch

Other links
Linkedin-in Youtube Facebook-f

© 2024. Syngene International Limited

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details